NRx Pharmaceuticals announced that the company has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101. With data-lock, as forecast in last week’s earnings call, the complete data set passed on for statistical analysis; top-line data release expected in April 2024. With positive data from this study and FDA comment, NRx becomes eligible to receive the balance of its first milestone (an additional $4M) from partners Alvogen and Lotus Pharmaceuticals. These partners would then be responsible for all future development costs in this indication. NRx retains rights for all other indications, including chronic pain and PTSD. NRx is then poised to receive $320M in further milestones along with mid-teen royalties on net sales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRX Pharmaceuticals trading halted, news pending
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Navigating the Minefield: Nrx Pharmaceuticals’ Tightrope Walk Between Safety Regulations and Operational Hazards
- NRX Pharmaceuticals Announces Reverse Stock Split
- NRx Pharmaceuticals sees FY23 EPS (40c), consensus (37c)